Fundraising Fox

Judo Bio

Cambridge, US · Founded 2021 · 34 employees on LinkedIn · 5 known investors

Judo Bio develops oligonucleotide medicines, including ligand-siRNA conjugate drugs, delivered to the kidney for systemic and renal diseases using its STRIKE (Selectively Targeting RNA Into KidnEy) platform. The company applies RNA-based therapeutics that harness a natural endogenous mechanism for receptor-mediated uptake by specific kidney cell types to silence disease-modifying genes.

BiotechHealthtech

Founders & leadership

Judo Bio was founded in 2021 by Andrew Fraley and Alfica Sehgal.

AF
Andrew FraleyCo-founder
AS
Alfica Sehgal
OC
OMMER CHOHANExecutive
JJ
JAMES JEFFREY GOATERExecutive
SR
Simon ReadCEO
WH
William Ho
CP
CHELSEA PLACE JOHNSONNamed on SEC filing

Board

KB
KEVIN BITTERMANBoard director
SBSAM BJORK
SAM BJORKinBoard directorPartner at Digitalis Ventures
HT
HUI TIANBoard director
GG
GEORGE GOLUMBESKIBoard director
AM
ANKIT MAHADEVIABoard director

Investors · 5

Atlas Venture✓ verifiedCambridge · $500K – $1M
Digitalis Ventures✓ verifiedNew York · $100K – $10M
The Column Group✓ verifiedSan Francisco · $30M
Droia Ventures✓ verifiedLeuven · $540K
YK BioventuresreportedBurlingame

Reported raises · per SEC filings

Form D private placements

$55M disclosed across 3 rounds · 2022–2024

▶$25MraisedAug 2024 · 21 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • GEORGE GOLUMBESKIDirector
  • OMMER CHOHANExecutive Officer
  • ANKIT MAHADEVIADirector
  • JAMES JEFFREY GOATERExecutive Officer, Director
  • KEVIN BITTERMANExecutive Officer, Director
  • SAM BJORKDirector
Amount sold
$25M
First sale
Jul 2024
Incorporated
Corporation, Delaware, 2021
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$5MraisedJun 2024 · 2 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • OMMER CHOHANExecutive Officer
  • CHELSEA PLACE JOHNSONDirector
  • KEVIN BITTERMANExecutive Officer, Director
  • JAMES JEFFREY GOATERExecutive Officer, Director
  • ANKIT MAHADEVIADirector
  • HUI TIANDirector
Offering amount
$5M
Amount sold
$5M
First sale
May 2024
Incorporated
Corporation, Delaware, 2021
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$25MraisedNov 2023 · 2 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • JAMES JEFFREY GOATERDirector
  • CHELSEA PLACE JOHNSONDirector
  • ANKIT MAHADEVIADirector
  • KEVIN BITTERMANExecutive Officer, Director
  • HUI TIANDirector
  • OMMER CHOHANExecutive Officer
Amount sold
$25M
First sale
Nov 2022
Incorporated
Corporation, Delaware, 2021
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Founder mafia

2 people who came through Judo Bio went on to found or lead other companies.

Kevin BittermanBoard of DirectorsFounded Editas MedicineJeff GoaterExecutive ChairFounded Atavistik Bio

Competitors · 2

by search overlap
Sudo Bio7 shared keywordsSudo Biosciences discovers and develops small-molecule medicines, including next-generation TYK2 inhibitors, for serious neurological and immunological conditions such as multiple sclerosis and immune-mediated inflammatory diseases. It focuses on medicinal chemistry, translational biology, and patient-centered drug development.
Ditto Biosciences6 shared keywordsDitto Bio uses AI to identify protein candidates from parasites and pathogens for treating autoimmune diseases. The company mines natural compounds from viruses, ticks, and worms whose immune-modulating properties have evolved over millions of years.

Companies competing with Judo Bio for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Judo Bio Launches with $100 Million and New CEO — The Pharma Navigator - Navigating The Key News Stories In Pharmathepharmanavigator.com · Oct 2024Judo Bio Launches with $100 Million to Develop Oligonucleotide Therapies that Target the Kidney - Global Genesglobalgenes.org · Oct 2024Kick Start: Judo Bio Takes a Page from Alnylam with $100M Launchgenengnews.com · Oct 2024Judo Bio Raises $100M in Seed and Series A Financingfinsmes.com · Oct 2024

Frequently asked questions

What does Judo Bio do?
Judo Bio develops oligonucleotide medicines, including ligand-siRNA conjugate drugs, delivered to the kidney for systemic and renal diseases using its STRIKE (Selectively Targeting RNA Into KidnEy) platform. The company applies RNA-based therapeutics that harness a natural endogenous mechanism for receptor-mediated uptake by specific kidney cell types to silence disease-modifying genes.
Who founded Judo Bio?
Judo Bio was founded by Andrew Fraley, Alfica Sehgal in 2021.
Who are Judo Bio's investors?
Judo Bio's investors include Atlas Venture, Digitalis Ventures, The Column Group, Droia Ventures, YK Bioventures.
How much funding has Judo Bio raised?
Judo Bio has disclosed $55M raised across 3 rounds.
Where is Judo Bio headquartered?
Judo Bio is headquartered in Cambridge, US.